Report #2835884

Overview

Sex

Male

Age

Age unknown

State

—

Recovered

Unknown

Vaccinated

—

Onset

—

Days to onset

—

Hospital days

—

Symptoms (2)

Symptom narrative

extra dose administered; No adverse event; This spontaneous report was received from other healthcare professional and refers to a male patient of unknown age. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On unspecified date, the patient was vaccinated with the first dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) (strength, dose, route, anatomical location, lot # and expiration date were not reported) for prophylaxis. On an unknown date, the patient received the second dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) (strength, dose, route, anatomical location, lot # and expiration date were not reported) for prophylaxis. On an unknown date in 2022, the patient received the third dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) (strength, dose, route, anatomical location, lot # and expiration date were not reported) for prophylaxis. On unknown date, the patient's physician recommended patient to receive a booster dose so he recently received one additional dose (fourth) of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) (strength, dose, route, anatomical location, lot # and expiration date were not reported) for prophylaxis (extra dose administered). The primary reporter did not think one booster dose would help patient and is asking if patient should receive two more doses of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9). No adverse event reported.